ArticleFrontiers in oncology2025
Study on the disease burden of lip and oral cancer attributable to tobacco use: based on the 2021 Global Burden of Disease study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To analyze the global, regional, and national epidemiological trends of lip and oral cancer (LOC) diseases attributable to tobacco from 1990 to 2021, with an emphasis on health inequalities. Methods: Utilizing the Global Burden of Disease (GBD) 2021 study, we evaluated the temporal trends in tobacco-attributable LOC mortality and disability-adjusted life years (DALYs). We further analyzed how LOC mortality and DALYs varied by age, period, and birth cohort. The Bayesian Age-Period-Cohort (BAPC) model was employed to project trends from 2021 to 2050. Additionally, decomposition analysis was conducted to identify key drivers of change, and health inequalities were assessed. Finally, frontier analysis was performed across global countries and regions. Results: From 1990 to 2021, tobacco-attributable LOC mortality and DALYs exhibited a significant declining trend globally (estimated annual percent change of -0.49 and -0.61, respectively). Population growth was the primary driver of increasing burden, while epidemiological transition mitigated the burden. Projections indicate that the burden will continue to decline by 2050, with low socio-demographic index (SDI) regions experiencing significantly higher burden compared to high SDI regions. Age effects showed a stepwise increase in mortality with advancing age, period analysis confirmed the sustained reduction in tobacco-related harm, and cohort studies revealed significantly lower risk among later-born populations. Cross-national analysis revealed a narrowing gap in burden between high and low SDI countries, yet countries such as Pakistan and Palau still exhibit substantial health benefit gaps. Conclusion: Although the global burden of tobacco-attributable LOC diseases shows a slow declining trend, low and middle SDI regions continue to maintain high burden levels. Strengthening tobacco control strategies in these regions are essential to narrow health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.